13F reference period
Q2 2026
Security Snapshot
OKYO Pharma Ltd - Ordinary Shares, no par value (OKYO) Institutional Ownership
CUSIP: G6724L116
13F Institutional Holders and Ownership History from Q2 2023 to Q3 2026
Institutions Reporting
19
Shares (Excl. Options)
6.49M
Full value: 6,493,711 · shares · 30 Jun 2026Price
$1.50
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares, no par value
- Symbol
- OKYO on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 6,493,711
- Total 13F value
- $9,740,568
- Portfolio coverage rank
- 0%
- Share change
- +103,972
- Value change
- +$155,537
- Number of holders
- 19
- Shares outstanding
- 52,174,143
- SEC-reported price per share
- $1.47
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- OKYO - OKYO Pharma Ltd - Ordinary Shares, no par value is tracked under CUSIP G6724L116.
- 19 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 12 to 19 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$10.29M
Full value: $10,287,479 · USD · 31 Mar 2026.$9.74M
Full value: $9,740,568 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 19 institutions filings for Q2 2026.
Security key
G6724L116
13F reference period
Q2 2026
13F holders
19
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
OKYO full holder history
OKYO Pharma Ltd SEC filings
OKYO Pharma Ltd company facts
OKYO Pharma Ltd insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G6724L116:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
OKYO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Sirenia Capital Management LP | 7.7% | $6,202,703 | 4,054,054 | Sirenia Capital Management LP | 31 Mar 2026 | |||
| Chernett Jorey | 9.5% | +21% | $11,824,823 | +$2,541,903 | 3,802,194 | +27% | Chernett Jorey | 31 Dec 2025 |
| Woodline Partners LP | 7% | $5,587,851 | 3,652,190 | Woodline Partners LP | 31 Mar 2026 | |||
| Fonda Laura Natalia Monica | 5% | $3,856,902 | 1,928,451 | LAURA NATALIA MONICA FONDA | 22 Jul 2025 | |||
| Dauntless Investment Group, LLC | 1.2% | -85% | $1,466,437 | -$6,066,133 | 471,523 | -81% | Dauntless Investment Group, LLC | 31 Dec 2025 |
As of 30 Jun 2026,
19
institutional investors reported holding
shares of
OKYO Pharma Ltd - Ordinary Shares, no par value (OKYO).
This represents
12%
of the company’s total
outstanding shares.
6.49M
Full value: 6,493,711 · shares · 30 Jun 202652.17M
Full value: 52,174,143 · shares · Stored outstanding share count13F concentration
Top 20 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
12%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Woodline Partners LP | 7% | 3,652,768 | +0.02% | 0.02% | $5,479,152 |
| Stonepine Capital Management, LLC | 1.7% | 862,996 | +1.5% | 0.99% | $1,294,494 |
| Maven Securities LTD | 1.6% | 809,317 | -31% | 0.08% | $1,213,976 |
| Balyasny Asset Management L.P. | 1.1% | 580,596 | -0.72% | 0% | $870,894 |
| Opaleye Management Inc. | 0.72% | 375,204 | 0.05% | $562,806 | |
| UBS Group AG | 0.11% | 55,009 | -8% | 0% | $82,514 |
| XTX Topco Ltd | 0.07% | 37,769 | +0.31% | 0% | $56,654 |
| CHOREO, LLC | 0.06% | 33,255 | 0% | $49,883 | |
| Quantinno Capital Management LP | 0.06% | 33,255 | 0% | $49,882 | |
| Cerity Partners LLC | 0.02% | 12,812 | 0% | 0% | $19,218 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.02% | 12,090 | 0% | 0% | $18,135 |
| RENAISSANCE TECHNOLOGIES LLC | 0.02% | 11,200 | 0% | $16,800 | |
| JANE STREET GROUP, LLC | 0.02% | 10,302 | 0% | $15,453 | |
| Steward Partners Investment Advisory, LLC | 0.01% | 6,000 | 0% | $9,000 | |
| EFG International AG | 0% | 923 | 0% | 0% | $1,385 |
| OSAIC HOLDINGS, INC. | 0% | 152 | 0% | 0% | $228 |
| Continuum Advisory, LLC | 0% | 50 | 0% | $75 | |
| MORGAN STANLEY | 0% | 10 | 0% | 0% | $15 |
| Caitong International Asset Management Co., Ltd | 0% | 3 | 0% | $4 | |
| Dauntless Investment Group, LLC | 0% | 0 | -100% | $0 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
14
Headline period
Q2 2026
Rows shown
1-14 of 14
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 33,255 | $42,899 | $1.29 | 1 | |
| 2026 Q2 | 6,493,711 | $9,740,568 | +$155,537 | $1.50 | 19 |
| 2026 Q1 | 6,389,739 | $10,287,479 | +$9,147,727 | $1.61 | 12 |
| 2025 Q4 | 665,294 | $1,147,535 | -$2,989,322 | $2.07 | 10 |
| 2025 Q3 | 2,570,815 | $5,141,930 | -$400,030 | $2.00 | 8 |
| 2025 Q2 | 2,770,797 | $1,479,794 | +$329,427 | $2.57 | 5 |
| 2025 Q1 | 2,075,082 | $2,634,954 | +$1,447,536 | $1.27 | 7 |
| 2024 Q4 | 1,026,179 | $1,179,953 | +$28,548 | $1.15 | 7 |
| 2024 Q3 | 1,001,353 | $1,021,431 | -$19,942 | $1.03 | 6 |
| 2024 Q2 | 1,010,912 | $1,210,177 | +$115,592 | $1.20 | 7 |
| 2024 Q1 | 913,582 | $1,363,796 | +$79,673 | $1.50 | 6 |
| 2023 Q4 | 855,098 | $1,513,021 | +$1,343,703 | $1.77 | 7 |
| 2023 Q3 | 95,254 | $175,728 | +$153,652 | $1.85 | 7 |
| 2023 Q2 | 11,933 | $13,669 | +$13,669 | $1.15 | 1 |